Clinical Trial Update: A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial in moderate to severe plaque psoriasis completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Idera Pharmaceuticals

Snippet

Sponsor: Idera Pharmaceuticals, Inc. | Conditions: Plaque Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2019-08-02